NASDAQ

Oculis Holding AG - Ordinary shares (OCS)

516 Thanks from members

Oculis Holding AG demonstrates strong clinical and capital momentum driven by its neuro-ophthalmology pivot, highlighted by Privosegtor's acquisition and robust cash runway into 2H 2029, though tempered by prior Phase 3 setbacks.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Explore →